THMO ThermoGenesis Holdings, Inc. Projected Price to Earnings

Corporate company logo of Cesca Therapeutics (THMO)

Cryopreservation patents and strict FDA oversight create significant barriers to entry for competitors, which determines the forward P/E multiple trend for ThermoGenesis (THMO). Collaboration with biobanks on tissue processing and independence from macroeconomic factors reinforce its status as a defensive asset. Meanwhile, the 0.00 metric reflects the current dynamics of investor expectations regarding the future earnings of ThermoGenesis.

THMO - thermogenesis.com Market Cap to Projected Earnings over the range 07/04/2022 - 08/04/2024

Financial and market metric breakdowns for Cesca Therapeutics (THMO)

- stock value and consensus price forecast:
Price Chart ThermoGenesis Holdings|THMO - Analyst Median Target
- market capitalization data:
Market Valuation ThermoGenesis Holdings, Inc.|THMO - Aggregate Business Value
- issuer book value statistics:
Book Value per Share ThermoGenesis|THMO - Book Valuation of Business|Market Capitalization to Book Value Ratio thermogenesis.com|THMO - Cumulative Company Assets
- debt and solvency information:
Total Debt to Equity Ratio ThermoGenesis|THMO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity ThermoGenesis|THMO - Company Total Debt|Debts to Book Capitalization ThermoGenesis Holdings, Inc.|THMO - Long-Term Debt|Company Short-Term Debts ThermoGenesis|Quick Ratio thermogenesis.com
- earnings and market ratios statistics:
THMO - Net Financial Result|Projected Future Earnings ThermoGenesis|THMO - Price to Earnings Ratio|Forward P/E Multiple ThermoGenesis Holdings Inc.|THMO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ThermoGenesis Holdings, Inc.|THMO - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months ThermoGenesis|THMO - Earnings per share for the trailing year|Quarterly EPS earnings growth thermogenesis.com|THMO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year ThermoGenesis
Fundamental company analysis:ThermoGenesis Holdings
Product sample of ThermoGenesis

ThermoGenesis (THMO) global diversification within the biobank automation sector stabilizes cash flows, which is directly reflected in market expectations. The company's consensus forward P/E illustrates the cost of one dollar of projected earnings, allowing for an assessment of the premium paid for future growth relative to current market capitalization. This chart helps investors timely identify the gap between actual business growth rates and market prices.

Competitors of ThermoGenesis (THMO)

Future Price to Earnings Abbott (ABT)|Market Cap to Projected Earnings Thermo Fisher Scientific Inc.|GE Healthcare Corp - Projected Price to Earnings|Market Cap to Future Earnings Ratio MTD (Mettler Toledo Inc)|Waters Corporation - Forward P/E Multiple|Market Cap to Projected Earnings bio-techne.com TECH|BRKR: Forward P/E Multiple|Projected Price to Earnings Azenta Inc|Projected Price to Earnings VREX|SMLR: Future Price to Earnings Multiple|Future Price to Earnings Butterfly Network, Inc. (BFLY)|Projected Price to Earnings mesalabs.com MLAB|Forward P/E Multiple QSI (Quantum-Si Incorporated)|Nano-X Imaging (NNOX) - Projected Price to Earnings Ratio|Quanterix Corp - Forward P/E Multiple|MASS (908 Devices Corporation) - Price to Future Earnings Ratio|CV: Forward P/E Multiple|MXCT - Market Cap to Projected Earnings|RPID (Rapid Micro Biosystems Inc.) - Forward P/E Multiple|Projected Price to Earnings Seer Inc (SEER)|Forward P/E Multiple HYPR|Forward P/E Multiple FONAR Corporation Inc (FONR)|Future Price to Earnings Daxor DXR|Spectral AI Inc. - Future Price to Earnings|VIVS: Projected Price to Earnings|Future Price to Earnings Multiple ACON (Aclarion Inc)|AKYA: Forward P/E Multiple|Projected Price to Earnings Ratio Talis Biomedical Corporation (TLIS)|Future Price to Earnings T2 Biosystems, Inc.